Last reviewed · How we verify
Danazol Capsules
At a glance
| Generic name | Danazol Capsules |
|---|---|
| Also known as | Optina, Cyclomen, Danocrine |
| Sponsor | Ampio Pharmaceuticals. Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PHASE3)
- The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis (PHASE2)
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) (PHASE3)
- Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes (PHASE2)
- A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema. (PHASE2)
- Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers. (PHASE1)
- Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy (PHASE2)
- Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |